Enzalutamide Monotherapy Induces PSA Response in Men with Hormone-Naïve Prostate Cancer
Monotherapy with the oral androgen receptor inhibitor, enzalutamide, was associated with significant prostate-specific antigen response in men with hormone-naïve prostate cancer, found research presented at the 2013 Genitourinary Cancers Symposium.